Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?

In this review we discuss recent progress in the development, testing, and clinical evaluation of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has been made in TB vaccine research and development: from a pipeline virtually empty of new TB candidate vaccines in the early 1990s, to an era in which a dozen novel TB vaccine candidates have been and are being evaluated in human clinical trials. In addition, innovative approaches are being pursued to further improve existing vaccines, as well as discover new ones. Thus, there is good reason for optimism in the field of TB vaccines that it will be possible to develop better vaccines than BCG, which is still the only vaccine available against TB.     

Antibiotic Use in Animal Agriculture: What Have We Learned and Where are We Going?

Antibiotics are enormously important for the humane and efficient production of food animals. These benefits are somewhat offset by the human and animal health antibiotic resistance risks posed by their use in animals. This article provides an overview of what we have learned about antibiotic resistance as an issue in animal agriculture and where that knowledge could lead us in the future. To preserve the effectiveness of antibiotics, more action is needed to ensure their prudent use, particularly in the case of antibiotic growth promoters and antibiotics deemed critically important for human and animal health.     

Chytrid Blinders: What Other Disease Risks to Amphibians Are We Missing?

Amphibian declines are occurring on a global scale, and infectious disease has been implicated as a factor in some species. Batrachochytrium dendrobatidis (Bd) has been associated with amphibian declines and/or extinctions in many locations, however, few of the studies have actually performed detailed pathological investigations to link the emergence of the disease with mortality rates large enough to cause the declines. Many studies are based solely on the presence of infection, not disease, because of the reliance on molecular tests for Bd. The emphasis of the importance of Bd combined with easy molecular tests has resulted in poor investigations into amphibian mortality and declines in many areas. The line between infection and disease has been blurred, and a step back to basic pathological and biological investigations is needed as other disease risks to amphibians, such as ranaviruses, are likely being missed. In this article, starting points for proper investigative techniques for amphibian mortalities and declines are identified and areas that need to be improved, especially communication between biologist and veterinarians involved in amphibian disease research, are suggested. It is hoped that this will start a much needed discussion in the area and lead to some consensus building about methodologies used in amphibian disease research.     

Risk Sensitivity in Behavior: Where Are We Now? Introduction to the Symposium

Risk-sensitive behavior is the phenomenon of animals exhibitingpreferences when offered choices whose outcomes differ in theirdegree of variance. It is now well demonstrated that many animalsare sensitive to differences in the magnitude of variance inrewards. A considerable body of literature on risk sensitivityhas been generated in recent years, encompassing theoreticaland empirical work, from both functional and mechanistic approaches.Nevertheless, it is less than clear how animal preferences forvariability are determined. It is therefore timely to look broadlyat what has been accomplished, and to identify the most promisingsynthetic approaches for future work.     

Animal Behavior: Who Will Croak Next?

A recent study with the predatory bat Trachops cirrhosus has shown the importance for this species of social learning about novel prey using auditory, rather than visual or olfactory, cues.     

Neuroprotective Effects of Protocatechuic Aldehyde against Neurotoxin-Induced Cellular and Animal Models of Parkinson’s Disease

Protocatechuic aldehyde (PAL) has been reported to bind to DJ-1, a key protein involved in Parkinson’s disease (PD), and exerts potential neuroprotective effects via DJ-1 in SH-SY5Y cells. In this study, we investigated the neuroprotective pharmacological effects of PAL against neurotoxin-induced cell and animal models of PD. In cellular models of PD, PAL markedly increased cell viability rates, mitochondrial oxidation-reduction activity and mitochondrial membrane potential, and reduced intracellular ROS levels to prevent neurotoxicity in PC12 cells. In animal models of PD, PAL reduced the apomorphine injection, caused turning in 6-OHDA treated rats, and increased the motor coordination and stride decreases in MPTP treated mice. Meanwhile, in an MPTP mouse model, PAL prevented a decrease of the contents of dopamine (DA) and its metabolites in the striatum and TH-positive dopaminergic neuron loss in the substantia nigra (SN). In addition, PAL increased the protein expression of DJ-1 and reduced the level of α-synuclein in the SN of MPTP lesioned mice. PAL also increased the spine density in hippocampal CA1 neurons. The current study demonstrates that PAL can efficiently protect dopaminergic neurons against neurotoxin injury in vitro and in vivo, and that the potential mechanisms may be related to its effects in increasing DJ-1, decreasing α-synuclein and its growth-promoting effect on spine density.     

The Quest for Renal Disease Proteomic Signatures: Where Should We Look?

Renal diseases are prevalent and important. However, despite significant strides in medicine, clinical nephrology still relies on nonspecific and inadequate markers such as serum creatinine and total urine protein for monitoring and diagnosis of renal disease. In case of glomerular renal diseases, biopsy is often necessary to establish the diagnosis. With new developments in proteomics technology, numerous studies have emerged, searching for better markers of kidney disease diagnosis and/or prognosis. Blood, urine, and renal biopsy tissue have been explored as potential sources of biomarkers. Some interesting individual or multiparametric biomarkers have been found; however, none have yet been validated or entered clinical practice. This review focuses on some studies of biomarkers of glomerular renal diseases, as well as addresses the question of which sample type(s) might be most promising in preliminary discovery phases of candidate proteins.